Home
Your First Visit

Therapies

Nutrition and You

Hormone Replacement
Meet the Staff
Patient Handouts
Map to Clinic
Email Us

Hormone Journal
Articles on Disease

Alternative Medical Research
On Chronic Disease

Signs of Low
Thyroid Function

Signs Of Sex Hormone Dysfunction

Adrenal Fatigue Slide Show

Nutrition and Health
Slide Show

Bio-identical Hormone
Therapy For Women
Slide Show

Medical Review Of
Growth Hormone Deficiency

 

Scheduling Your First Appointment?

You can download and fill out our patient application form and bring it in with you to your first appointment.

Please complete this health questionnaire before your scheduled appointment. Dr. Jace will review it with you at the time of your initial visit.

Click here to download the questionnaire.

Click here to visit
our new supplement
store for products
to improve your health!

 


LDA

Please note: LDA is not approved by the Food and Drug Administration.

Dr. Shrader’s LDA: A Dramatically Effective Immunotherapy
            LDA is used to treat all types of allergy, sensitivity and intolerance to inhalants (pollens, dust, mites, danders, etc.), foods and chemicals.  It is not only used to treat such conditions as Hay Fever, Asthma, Food Allergy, but other conditions of inflammation as well.  Diseases of inflammation such as Arthritis, Autoimmune Disease, MS, Environmental Illness, Irritable Bowel Syndrome, and Hypertension have been shown to respond to treatment.  Any Inflammation caused by allergies and sensitivity will stress the Endocrine System and contribute to hormone dysfunction. Many patients with Endocrine Disease will also benefit from this type of therapy.

Comparison of LDA to conventional immunotherapy

Conventional “escalating dose” (where the dose is started “low” – usually 1 to 10,000, and increased over time to as high as 1 to 10, 1 to 20 or 1 to 100) immunotherapy is employed in this country primarily to treat hay fever, cat and dust mite allergy, which are primarily IgE mediated.  This type of therapy works by causing the patient to produce “blocking antibody” (specific IgG), which inhibits the histamine-releasing ability (which produces the allergy symptoms) of the mast cell.  In order to produce adequate levels of blocking antibody, studies have shown that it requires administration of very high doses of allergen.  Therefore, treatment using this method often causes intolerable swelling and other side effects before clinical efficacy can be attained, and can be dangerous due to the risk of severe reactions such as anaphylaxis, massive swelling, collapse and death.


            In England, "conventional" (escalating dose) immunotherapy has now been banned by the Medicines Commission (26 deaths had been reported) except when given in a hospital setting where emergency resuscitation equipment is immediately available. In the United States, at least 60 deaths have been recorded since treatment began in the 1930s as a result of conventional immunotherapy, but the actual number is likely closer to 100.


LDA immunotherapy, however, is cell-mediated and extremely low dose.  The highest ending dose (“maintenance” dose) of LDA is at least 10 million times less than the standard maintenance dose for conventional immunotherapy.  EPD/LDA immunotherapy is now the only allergy immunotherapy permitted to be used in a physician’s office outside a hospital setting in the United Kingdom.


            Conventional escalating dose immunotherapy generally does not generally offer long lasting benefit, and it cannot easily be stopped without the return of significant symptoms in 3 to 12 months. 

It has been suggested by several previous studies of EPD/LDA immunotherapy that this method of treatment can produce much longer lasting desensitization than does conventional immunotherapy, with treatments lasting as long as 1-5 years.  Historically, approximately half of patients who have responded to LDA/EPD were able to stop permanently after between 10 and 20 treatments.


Conventional immunotherapy must usually be administered twice weekly for the first four to six months of treatment.  Once the very high maintenance dose is reached, the treatment interval may be extended to once every two weeks, but rarely less often.


LDA immunotherapy, on the other hand, is only administered every two months or less often, according to previous published studies.  Treatment is required only every two months initially for a period of approximately 12 months.  After that time, the treatment interval may generally be extended to three months or longer.  Most adults with significant problems require 16 of 18 treatments at intervals of three months or longer, at which time treatment may be discontinued or significantly reduced (intervals of a year or less often are common) for the majority of patients.


            LDA/EPD includes mixtures of antigens developed by Dr. McEwen over the past 30 years that may act quite "universally."  This means patients allergic or intolerant to most substances have responded to treatment.  Available mixtures include inhaled pollens, danders, dust and mites, a wide range of bacteria, fungi, yeast (including candida species), molds, foods, many food additives, most common chemicals (except pesticides and herbicides), formaldehyde, detergents (for contact skin sensitivity), wood terpenes, and mosquito (which likely cross reacts with other non-venomous insects).  LDA/EPD treatment for bee venom anaphylaxis is currently under investigation in England.
            LDA/EPD has the distinct apparent advantage that it appears to effectively treat a very wide variety of immune and autoimmune disorders (and others not generally perceived to be immune-related), including illnesses that respond poorly -- or not at all -- to other methods of treatment of any kind. Some of the conditions being treated successfully include hay fever [8,11, 14,15,25], dust mite allergy [16,20] perennial rhinitis [6], asthma [6,14,16,20], urticaria ("hives") [14], eczema (dermatitis) of most all varieties [14], angioedema (swelling of the face, lips, etc.) [6,14], anaphylactic reactions (life-threatening swelling, usually involving the airways) to most known substances [14], food (or food additive/preservative) allergy or intolerance [7,12], adverse responses to chemicals ("multiple chemical sensitivity" or "MCS") [14], ADHD (Attention Deficit Hyperactivity Disorder) [13,14], autism, Tourette’s syndrome, irritable bowel disorders, Crohn's Disease, ulcerative colitis [7] migraine and other headaches [14,16,17,21] rheumatoid arthritis, ankylosing spondylitis and systemic lupus erythematosis [27], to name just a few.

EPD References

  1. McEwen LM. Ganderton MA. Wilson CW. Black JH. Hyaluronidase in the treatment of allergy. British Medical Journal. ii: 507-8, 1967.
  2. McEwen LM. Starr MS. Enzyme potentiated hyposensitization I: The effect of pre-treatment with beta-glucuronidase, hyaluronidase and antigen on anaphylactic sensitivity of guinea pigs, rats and mice.  International Archives of Allergy.  42:152-8, 1972.
  3. McEwen LM. Enzyme potentiated hyposensitization II: Effect of glucose, glucosamine, N-acetylamino-sugars and gelatin on the ability of beta- glucuronidase to block the anamnestic response to antigen in mice.  Annals of Allergy. 31:79-83,1973.
  4. McEwen LM. Effects of sugars and diols on enzyme potentiated desensitization. Journal of Physiology. 230(1): 65-6, 1973 Apr.
  5. McEwen LM. Nicholson M. Kitchen I. White S. Enzyme potentiated hyposensitization III: Control by sugars and diols of the immunological effect of beta-glucuronidase in mice and patients with hay fever.  Annals of Allergy. 31(11), 543-50, 1973.
  6. McEwen LM. Nicholson M. Kitchen I. O’Gorman J. White S. Enzyme potentiated hyposensitization IV: Effect of protamine on the immunological behavior of beta-glucuronidase in mice and patients with hay fever.  Annals of Allergy.  34:290-5,1975.
  7. McEwen LM. Enzyme potentiated hyposensitization V: Five case reports of patients with acute food allergy. Annals of Allergy. 35:98-103,1975.
  8. McEwen LM. A double-blind controlled trial of enzyme potentiated hyposensitization for the treatment of ulcerative colitis. Clinical Ecology. 5(2): 47-51, 1987.
  9. McEwen LM. Hyposensitization. In: Brostoff J and Challacombe SJ., Eds. Food allergy and intoleranceLondon; Bailliere Tindall, 985-94, 1987.
  10. Fell P. Brostoff JA. Single dose desensitization for summer hay fever.  European Journal of Clinical Pharmacology. 38: 77-9,1990.
  11. Eaton KK. Preliminary studies with enzyme potentiated desensitization in canine atopic dermatitis.  Environmental Medicine. 8:140-1,1991.
  12. Longo G. Poli F. Bertoli G. Efficacia clinica di UN novo trattemento iposensibilizzante, EPD (enzyme potentiated desensitization) nella terapia Della pollinosi.  Reforma Medica.  107:171-6,1992.
  13. Eggar J. Stolla A. McEwen LM.  Controlled trial of hyposensitization in children with food-induced hyperkinetic syndrome. Lancet. 339:1150-3, 1992 May 9.
  14. Shrader Jr. WA.  McEwen LM.  Enzyme potentiated desensitization: A sixteen month trial of therapy with 134 patients. Environmental Medicine. 9 (3&4): 128-38, 1993.
  15. Angelini G. Curatoli G. D’Argento V. Vena GA. Pollinosi: una nuova metodica di immunoterapia.  Medit. J. Surg. Med., 253-6, 1993
  16. Eggar J. Stolla A. McEwen L.M. Hyposensibilisierung bei nahrungsmittelinduzierter migrane. Actuelle Neuropadiatrie. 1992.  A. Lishka, G. Bernett (Eds.) 1992. 287-291. Ciba-Geigy Verlag, Wehr 1993.
  17. Eggar J. Stolla A. McEwen LM. Controlled trial of hyposensitization in children with food induced migraine. Cephalgia.13: Suppl. 216, 1993.
  18. Di Stanislao C. Mazzocchetti E. Bologna G Chimenti S. EPD secondo McEwen: Studio cliniico, istologia e immunoistochimico. Bollentino de dermatologia allergologia e professionale, 2, 1994
  19. Astarita C. et al. Effects of enzyme potentiated desensitization in the treatment of pollinosis: A double-blind placebo-controlled trial.  Journal of Investigational Allergology and Clinical Immunology 6(4): 248-255, 1996 July-Aug.
  20. Cantani A. Vanda Ragno V. Monteleone A. Lucenti P. Businco L. Enzyme-potentiated desensitization in children with asthma and mite allergy: A double-blind study.  Journal of Investigational Allergology and Clinical Immunology. 6(4): 270-76, 1996 Jul.-Aug.
  21. Galland L. McEwen L.M.  A role for food intolerance in childhood migraine. World Ped. & Child Care. 6: 2-8, 1996.
  22. Pulec JL. Enzyme-potentiated desensitization: a major breakthrough [editorial].  Ear, Nose, & Throat Journal. 75(10): 640, 1996 Oct.
  23. Caramia G. Franceschini F. Cimarelli ZA. Ciucchi MS. Gagliardini R. Ruffini E. The efficacy of E.P.D., a new immunotherapy, in the treatment of allergic diseases in children. Allergie et Immunologie. 28(9): 308-10, 1996 Nov.
  24. Ippoliti F. Rivi R. Businco L. Effect of preseasonal enzyme potentiated desensitization (EPD) on plasma IL-6 and IL-10 in grass pollen-sensitive asthmatic children. Allergie et Immunologie; 29(5): 120, 123-25, 1997.
  25. Di Stanislao C. Mazzocchetti E. Bologna G Chimenti S. A double-blind, placebo-controlled study of preventative immunotherapy with EPD in the treatment of seasonal allergic disease.  Allergie et immunologie. 29(2): 39-42, 1997.
  26. Ward WA. Enzyme potentiated desensitization (EPD): a potential revolution in allergy care. Current Opinion in Otolaryngology & Head and Neck Surgery. 8:273-6, 2000.
  27. Shrader, Jr. WA.  The use of bacterial antigen EPD immunotherapy for the treatment of rheumatoid arthritis and reactive arthritis: the role of molecular mimicry (unpublished), 1996, revised 1998, 2000.

 

 

[ Home ] [Supplement Store][ Your First Visit ] [ Therapies ] [ Nutrition and You ] [ PATHE ] [Prolotherapy ] [Mesotherapy] [IonCleanse]
[EWOT] [Limbic Stress Assesment] [LDA] [Heart Rate Variability] [Magnatherm Therapy]
[Energetic Balancing] [Colon Hydrotherapy] [Hormone Replacement] [ Chelation ][ Meet the Staff ] [ Email Us ]